A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant

Saran, 2019, US Renal Data System 2018 annual data report: Epidemiology of Kidney Disease in the United States, Am J Kidney Dis, 73, A7, 10.1053/j.ajkd.2019.01.001 Chapman, 2013, Cancer in the transplant recipient, Cold Spring Harb Perspect Med, 3, a015677, 10.1101/cshperspect.a015677 Engels, 2019, Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer, Am J Transplant, 19, 3223, 10.1111/ajt.15495 Sharma, 2015, The future of immune checkpoint therapy, Science, 348, 56, 10.1126/science.aaa8172 Lipson, 2014, Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma, J Clin Oncol, 32, e69, 10.1200/JCO.2013.49.2314 Lipson, 2016, Tumor regression and allograft rejection after administration of anti-PD-1, N Engl J Med, 374, 896, 10.1056/NEJMc1509268 Abdel-Wahab, 2019, Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature, J Immunother Cancer, 7, 106, 10.1186/s40425-019-0585-1 Manohar, 2020, Systematic review of the safety of immune checkpoint inhibitors among kidney transplant patients, Kidney Int Rep, 5, 149, 10.1016/j.ekir.2019.11.015 d’Izarny-Gargas, 2020, Efficacy and tolerance of immune checkpoint inhibitors in transplant patients with cancer: a systematic review, Am J Transplant, 20, 2457, 10.1111/ajt.15811 Barnett, 2017, Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab, N Engl J Med, 376, 191, 10.1056/NEJMc1614298 Seethapathy, 2019, The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors, Clin J Am Soc Nephrol, 14, 1692, 10.2215/CJN.00990119 Cortazar, 2020, Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study, J Am Soc Nephrol, 31, 435, 10.1681/ASN.2019070676 Fairfax, 2020, Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma, Nat Med, 26, 193, 10.1038/s41591-019-0734-6 Euvrard, 2012, Sirolimus and secondary skin-cancer prevention in kidney transplantation, N Engl J Med, 367, 329, 10.1056/NEJMoa1204166 Dantal, 2018, Sirolimus for secondary prevention of skin cancer in kidney transplant recipients: 5-year results, J Clin Oncol, 36, 2612, 10.1200/JCO.2017.76.6691 Esfahani, 2019, Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation, Nat Commun, 10, 4712, 10.1038/s41467-019-12628-1 Danesh, 2020, Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy, Cancer Immunol Immunother, 69, 1937, 10.1007/s00262-020-02644-2 Ito, 2005, Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo, J Immunol, 174, 6648, 10.4049/jimmunol.174.11.6648 Yang, 2008, Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy, Circulation, 117, 660, 10.1161/CIRCULATIONAHA.107.741025 Riella, 2011, Essential role of PDL1 expression on nonhematopoietic donor cells in acquired tolerance to vascularized cardiac allografts, Am J Transplant, 11, 832, 10.1111/j.1600-6143.2011.03451.x Seethapathy, 2020, Incidence and clinical features of immune-related acute kidney injury in patients receiving programmed cell death ligand-1 inhibitors, Kidney Int Rep, 5, 1700, 10.1016/j.ekir.2020.07.011 Arbour, 2018, Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer, J Clin Oncol, 36, 2872, 10.1200/JCO.2018.79.0006 Ricciuti, 2019, Immune checkpoint inhibitor outcomes for patients with non-small-cell lung cancer receiving baseline corticosteroids for palliative versus nonpalliative indications, J Clin Oncol, 37, 1927, 10.1200/JCO.19.00189 Vermorken, 2008, Platinum-based chemotherapy plus cetuximab in head and neck cancer, New Engl J Med, 359, 1116, 10.1056/NEJMoa0802656 Lanz, 2019, Aggressive squamous cell carcinoma in organ transplant recipients, JAMA Dermatol, 155, 66, 10.1001/jamadermatol.2018.4406 South, 2014, NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis, J Invest Dermatol, 134, 2630, 10.1038/jid.2014.154 Goodman, 2017, Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers, Mol Cancer Ther, 16, 2598, 10.1158/1535-7163.MCT-17-0386 Migden, 2018, PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma, N Engl J Med, 379, 341, 10.1056/NEJMoa1805131 Larkin, 2019, Five-year survival with combined nivolumab and ipilimumab in advanced melanoma, N Engl J Med, 381, 1535, 10.1056/NEJMoa1910836 Vajdic, 2014, Survival after cutaneous melanoma in kidney transplant recipients: a population-based matched cohort study, Am J Transplant, 14, 1368, 10.1111/ajt.12716 Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N Engl J Med, 372, 2521, 10.1056/NEJMoa1503093 Wolchok, 2017, Overall survival with combined nivolumab and ipilimumab in advanced melanoma, N Engl J Med, 377, 1345, 10.1056/NEJMoa1709684 Nankivell, 2010, Rejection of the kidney allograft, N Engl J Med, 363, 1451, 10.1056/NEJMra0902927 Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assoc, 53, 457, 10.1080/01621459.1958.10501452